Abstract
The protocols of Rosen and collaborators have been used for several years in Scandinavia [1], with the exception of our institution, where adjuvant IFN has been utilized for 20 years [2]. The present report is an update of our IFN-treated osteosarcoma series conducted over the period 1971–1984; control patients representing a high-dose chemotherapy group and a nonadjuvant group are also presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Solheim Ö, Alvegärd TA, Elomaa J. Adjuvant chemotherapy for osteosarcoma. A preliminary report from the Scandinavian Sarcoma Group. Acta Oncol 28(Suppl 2):53–57, 1989.
Strander H, Bauer HCF, Brosjö O, et al. Osteosarcoma management and interferon. In: Clinical Aspects of Interferons. Revel M, Ed. Kluwer Boston, 1988, pp 165–181.
Ingimarsson S, Cantell K, Strander H. Side effects of long term treatment with human leukocyte interferon. J Infect Dis 140:560–563, 1979.
Brouty-Boyé D, Wybier-Franqui J, Nardeux P, et al. Interferon-induced phenotypic changes in human tumor cells relative to the effects of interferon on c-ras oncogen expression. J Interfer Res 6:461–471, 1986.
Kirstein M, Baglioni C. Tumor necrosis factor stimulates proliferation of human osteosarcoma cells and accumulation of c-myc messenger RNA. J Cell Physio 134:479–484, 1988.
Hudson MM, Snyder JS, Knowles RD, et al. The effect of adriamycin therapy in vitro and in vivo on monocyte activation by liposome-encapsulated lymphokines. Proc Annu Meet Am. Assoc Cancer Res 28:220, 1987.
Strander H Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 19:468–473, 1987.
Crane JL Jr., Glasgow LA, Kern ER, Youngner J. Inhibition of murine osteogenic sarcomas by treatment with type I and type II interferon. J Natl Cancer Inst 61:871–874, 1978.
Taylor GN, Kern ER, Braaten B, et al. Failure of interferon to inhibit plutonium-induced osteosarcomas in mice. J Natl Cancer Inst 72:1137–1140, 1984.
Brosjö O, Bauer HCF, Brostróm L-Å, et al. Growth inhibition of human osteosarcomas in nude mice by human interferon-α: Significance of dose and tumor differentiation. Cancer Res 47:258–262, 1987.
Bauer HC, Brosjö O, Strander H. Comparison of growth inhibiting effect of natural and recombinant interferon-alpha on human osteosarcomas in nude mice. J Interferon Res 7:365–369, 1987.
Masuda S, Fukuma H, Beppu Y. Antitumor effect of human leukocyte interferon on human oseosarcoma transplanted into nude mice. Eur J Cancer Clin Oncol 19:1521–1528, 1983.
Hofmann V, Groscurth P, Morant R, et al. Effects of leukocyte interferon (E. coli) on human bone sarcoma in vitro and in the nude mouse. Eur J Cancer Clin Oncol 21:859–863, 1985.
Winkler K, Beron G, Kotz R, et al. Adjuvant and neoadjuvant chemotherapy of osteosarcoma: experience of the German-Austrian cooperative osteosarcoma studies (COSS). Monogr Ser Eur Org Res Treat Cancer 16:275–288, 1986.
Caparros B, Rosen G, Cunningham-Rundles S. Phase II trial of interferon (IFN) on metastatic osteogenic sarcoma. Proc Am Assoc Cancer Res 23:121, 1982.
Edmonson JH, Long HJ, Frytak S, et al. Phase II study of recombinant aipha-2a interferon in patients with advanced bone sarcomas. Cancer Treat Rep 71:747–748, 1987.
Ito H, Murakami K, Yanagawa T, et al. Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Case reports. Cancer 46:1562–1565, 1980.
Pastorino U, Valente M, Gasparini M, et al. Lung resection as salvage treatment for metastatic osteosarcoma. Tumori 74:201–206, 1988.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Strander, H. et al. (1993). Adjuvant interferon treatment in human osteosarcoma. In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3518-8_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6561-7
Online ISBN: 978-1-4615-3518-8
eBook Packages: Springer Book Archive